Rivastigmine in Parkinson's disease dementia

Expert Review of Neurotherapeutics

Volumn 8, Issue 8, 2008, Pages 1181-1188

  Lalli, Stefania ^a   Albanese, Alberto ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Cholinesterase inhibitor; Dementia; Lewy body disease; Parkinson's disease; Rivastigmine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; ASTHENIA; ATTENTION; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONFUSION; CONSTIPATION; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ADSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FALLING; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEALTH CARE COST; HUMAN; HYPOTENSION; LEWY BODY; MALAISE; MULTIFACTORIAL INHERITANCE; NAUSEA; NERVE CELL; NEUROPATHOLOGY; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; SYNCOPE; TREMOR; VOMITING; WEAKNESS;

BRAIN; CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES;

EID: 49449091311     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.8.1181     Document Type: Review

References (59)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K et al. How common are the "common" neurologic disorders? Neurology 68(5), 326-337 (2007).
2. Mayeux R, Denaro J, Hemenegildo N et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol. 49(5), 492-497 (1992).
3. Aarsland D, Andersen K, Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387-392 (2003). • Prospective study regarding descriptive epidemiology of dementia associated with Parkinson's disease (PD).
4. Marder K, Tang MX, Cote L et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch. Neurol. 52, 695-701 (1995).
5. Hughes TA, Ross HF, Musa S et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54(8), 1596-1602 (2000).
6. Aarsland D, Andersen K, Larsen JP et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 56(6), 730-736 (2001).
7. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord. 19(9), 1043-1049 (2004).
8. Caparros-Lefebvre D, Pécheux N, Petit V et al. Which factors predict cognitive decline in Parkinson's disease? J. Neurol. Neurosurg. Psychiatry 58(1), 51-55 (1995).
9. Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol. 61(12), 1906-1911 (2004).
10. Lieberman A. Are dementia and depression in Parkinson's disease related? J. Neurol. Sci. 248, 138-142 (2006).
11. Weintraub D, Moberg PJ, Duda JE et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J. Am. Geriatr. Soc. 52, 784-788 (2004).
12. Foltynie T, Brayne CE, Robbins TW et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127, 550-560 (2004).
13. Siddiqui MA, Wagstaff AJ. Rivastigmine in Parkinson's disease dementia: profi le report. Drugs Aging 24(3), 255-259 (2007).
14. Bohnen NI, Kaufer DI, Ivanco LS et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 60(12), 1745-1748 (2003). • A PET study assessing that cortical cholinergic dysfunction in PD dementia (PDD) seems more severe than in Alzheimer's disease.
15. Taylor P. Anticholinesterase agents. In: Goodman's and Gilman's (9th Ed). The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds), McGraw-Hill, New York, USA, 161-175 (1996). • Pharmacological mechanisms of cholinesterase inhibitors.
16. Grutzendler J, Morris J. Cholinesterase inhibitors for Alzheimer's disease. Drugs 61, 41-52 (2001).
17. McKeith I, Del Ser T, Spano P et al. Effi cacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356, 2031-2036 (2000). •• Large clinical trial showing the effi cacy of rivastigmine in Lewy body dementia.
18. Burn DJ, McKeith I. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov. Disord. 18(Suppl. 6), S72-S79 (2003).
19. McKeith I, Mosimann UO. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat. Disord. 10, S15-S18 (2004).
20. Giladi N, Shabtai H, Gurevich T et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol. Scand. 108(5), 368-373 (2003).
21. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord. 16(6), 1171-1195 (2001).
22. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry 18 (10), 937-941 (2003).
23. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin. Neuropharmacol. 25(2), 107-110 (2002).
24. Emre M, Aarsland D, Albanese A et al. Rivastigmine for the dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518 (2004). •• First large controlled study evaluating rivastigmine in PDD.
25. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry 76(7), 903-904 (2005).
26. McKeith IG, Burn D. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. In: Neurologic Clinics. DeKosky ST (Ed.), WB Sauders, PA, USA, 865-883 (2000).
27. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2, 229-237 (2003). •• Important review on several aspects of dementia in PD.
28. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 67, 1605-1611 (2006).
29. Hegemann-Richard I, Papka M, Rubio A et al. Parkinson's disease and dementia with Lewy bodies one disease or two? Mov. Disord. 17, 1161-1165 (2002).
30. McKeith I, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (12), 1863-1872 (2005).
31. Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22, 1689-1707 (2007). • Revised diagnostic criteria for dementia in PD.
32. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 13, 391-411 (1998).
33. Miyasaki J M, Shannon K, Voon V et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7), 996-1002 (2006). •• A worthy review of the available evidence of cognitive and psychological impairment in PD.
34. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51, 745-752 (1988).
35. Poewe W, Wolters E, Emre M et al. Long-term benefi ts of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov. Disord. 21(4), 456-461 (2006). • Extension study evaluating long term effects of rivastigmine.
36. Jann MW. Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20, 1-12 (2000).
37. McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer's disease. Br. J. Clin. Pharmacol. 48(4), 471-480 (1999).
38. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 13, 391-411 (1998).
39. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 69(4 Suppl. 1), S10-S13 (2007).
40. Cummings J, Winblad B. A Rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev. Neurother. 7, 1457-1463 (2007).
41. Hossain M, Jhee SS, Shiovitz T et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin. Pharmacokinet. 41(3), 225-234 (2002).
42. Cutler NR, Polinsky RJ, Sramek JJ et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol. Scand. 97(4), 244-250 (1998).
43. Schran HF, Habucky K, Mancione LC et al. The effects of renal and hepatic impairment on the disposition of acetylcholinesterase SDZ ENA 713 [abstract]. Pharm. Res. 13, S-428 (1996).
44. Mesulam MM, Guillozet A, Shaw P et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110(4), 627-639 (2002).
45. Mesulam MM. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In: Cholinesterases and Cholinesterase Inhibitors. Giacobini E (Ed.), Martin Dunitz, London, 121-138 (2000).
46. Greig NH, Utsuki T, Ingram DK et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc. Natl Acad. Sci. USA 102, 17213-17218 (2005).
47. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive defi cits in dementia with Lewy bodies. Neurology 60(11), 1852-1853 (2003).
48. Ceravolo R, Volterrani D, Frosini D et al. Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J. Neural. Transm. 113, 1787-1790 (2006).
49. Kuhl DE, Koeppe RA, Snyder SE et al. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann. Neurol. 59(1), 13-20 (2006).
50. Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. 21, 1899-1907 (2006). • First study addressing the hypothesis that visual hallucinations predict greater therapeutic benefit from rivastigmine in PDD.
51. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst. Rev. (1), CD004747 (2006).
52. Burns A, O'Brien J, BAP Dementia consensus group et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for psychopharmacology. J. Psychopharmacol. 20, 732-755 (2006).
53. Mercier F, Lefèvre G, Huang HL. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr. Med. Res.Opin. 23, 3199-3204 (2007).
54. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 22, 456-467 (2007).
55. Lefèvre G , Sedek G, Jhee SS et al. Pharmacokinetics and pharmacodynamics of novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin. Pharmacol. Ther. 83, 106-114 (2008).
56. Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Neurology 60(11), 1852-1853 (2003). • Systematic reviews of the studies on cholinesterase inhibitors and rivastigmine.
57. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am. J. Psychiatry 157(1), 4-15 (2000).
58. Novartis Europharm Limited. Product information (EU): Exelon® (rivastigmine tartarate) capsules and oral solution www.emea.europa.eu/ humandocs/Humans/EPAR/exelon/exelon.htm
59. US Food and Drug Administration. FDA approved drug products www.fda.gov